Robin Allgren

Dr. Allgren has over 20 years of experience in clinical development and regulatory affairs for biotech, pharma, medical device, diagnostic and stem cell products as Founder of Breakthrough Bio Development, Senior VP of Development (Ansata Therapeutics, Inc.), VP of Clinical Research & Medical Affairs (Innercool Therapies, Inc.), VP of Clinical Development (SkyePharma, Inc.), and VP of Clinical Research (Scios, Inc.). She possesses extensive experience in the design and execution of Phase 1-4 clinical studies and FDA interactions, including IND and NDA preparation as well as in Pharmacovigilance/ Medical Monitoring activities as well as in the development of devices for intravascular intra-operative temperature management. Therapeutic areas included CNS disease (stroke, Parkinson’s Disease), cardiovascular disease, oncology, nephrology, dermatology, inflammatory, anti-infective, pain management, GI, and endocrine. Marketed FDA-approved products include Natrecor®, DepoCyt®, DepoDur™ and the Celsius Control™ System. Dr. Allgren holds a MD/PhD from Stanford Medical School and a MBA in Health Services Management from Golden Gate University in San Francisco.